Identification
Name Pipobroman
Accession Number DB00236 (APRD00693)
Type small molecule
Description An antineoplastic agent that acts by alkylation. [PubChem]
Structure
Categories (*)
Molecular Weight 356.054
Groups approved
Monoisotopic Weight 353.95785306
Pharmacology
Indication For the treatment of polycythaemia vera and refractory chronic myeloid leukaemia.
Mechanism of action The mechanism of action is uncertain but pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death.
Absorption Well absorbed from the GI tract.
Protein binding Not Available
Biotransformation Not Available
Route of elimination Not Available
Toxicity Symptoms of overdose include hematologic toxicity, especially with chronic overdosage.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Acebutolol Antagonism
Atenolol Antagonism
Betaxolol Antagonism
Bevantolol Antagonism
Bisoprolol Antagonism
Carteolol Antagonism
Carvedilol Antagonism
Esmolol Antagonism
Labetalol Antagonism
Metoprolol Antagonism
Nadolol Antagonism
Oxprenolol Antagonism
Penbutolol Antagonism
Pindolol Antagonism
Practolol Antagonism
Propranolol Antagonism
Sotalol Antagonism
Timolol Antagonism
Food Interactions Not Available
DNA
Name DNA
Gene Name Not Available
Pharmacological action yes
Actions cross-linking/alkylation
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Yellin TO: Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12. - Pubmed
  • Passamonti F, Lazzarino M: Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Leuk Lymphoma. 2003 Sep;44(9):1483-8. - Pubmed
DTHybrid score Not Available